Miller, and A. James, M. Sydes, N. Clarke et al. Gillessen, A. Omlin, G. Attard et al. Mucci, J. Hjelmborg, J. Harris et al. Robinson, E. Van Allen, Y. Wu et al. Kote-Jarai, D. Leongamornlert, D. Leongamornlert et al. Eeles, C. Goh, E. Castro et al. Reinhardt and M. Jackson and J. Reinhardt and B. Dietlein, L. Thelen, and H. Roy, J. Chun, and S. Castro, C. Goh, D. Olmos et al. Mateo, S. Carreira, S. Sandhu et al. Pomerantz, S. Jia et al. Pritchard, J. Mateo, M. Walsh et al.
Abeshouse, J. Ahn, R. Akbani et al. Mateo, G. Seed, C. Bertan et al. Nombela, R. Lozano, A. Aytes et al. Annala, W. Struss, E. Warner et al. Mateo, H. Cheng, H. Beltran et al. Antonarakis, C. Lu, B. Luber et al. Castro, N. Romero-Laorden, A. Del Pozo et al. Byrski, J. Gronwald, T. Huzarski et al. Von Minckwitz, A. Schneeweiss, S.
Loibl et al. These cancers are associated with somatic variants that occur only in certain cells in the prostate. When prostate cancer is related to inherited gene changes, the way that cancer risk is inherited depends on the gene involved. For example, variants in the BRCA1 , BRCA2 , and HOXB13 genes are inherited in an autosomal dominant pattern , which means one copy of the altered gene in each cell is sufficient to increase a person's chance of developing cancer.
In other cases, the inheritance of prostate cancer risk is unclear. It is important to note that people inherit an increased risk of cancer, not the disease itself. Not all people who inherit variants in these genes will develop cancer. Genetics Home Reference has merged with MedlinePlus. Learn more. The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.
Prostate cancer. From Genetics Home Reference. Description Prostate cancer is a common disease that affects men, usually in middle age or later. Frequency About 1 in 7 men will be diagnosed with prostate cancer at some time during their life. Causes Cancers occur when genetic variants also known as mutations build up in critical genes, specifically those that control cell growth and division or the repair of damaged DNA. Inheritance Many cases of prostate cancer are not related to inherited gene changes.
Research Studies from ClinicalTrials. Prostate cancer: germline prediction for a commonly variable malignancy. BJU Int. Epub Sep The mutational landscape of prostate cancer. Eur Urol. Epub May The prostate cancer genome: perspectives and potential. Urol Oncol. Epub Nov New strategies in prostate cancer: translating genomics into the clinic.
Clin Cancer Res. Epub Dec Asian J Androl. Epub Apr The genetic epidemiology of prostate cancer and its clinical implications. Eur Urol 71 : — The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 19 : R — R Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer Res 73 : — Tumour heterogeneity in the clinic.
Enzalutamide in metastatic prostate cancer before chemotherapy. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35 : 40 — Beltran H , Demichelis F. Prostate cancer: intrapatient heterogeneity in prostate cancer.
Nat Rev Urol 12 : — Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1 : — A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer NEPC.
Ann Oncol 27 : LBA Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22 : — Benafif S , Eeles R. Genetic predisposition to prostate cancer. Br Med Bull : 75 — A review of prostate cancer genome wide association studies GWAS.
Cancer Epidemiol Biomarkers Prev 27 : — Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 49 : — Expression signature of the mouse prostate. J Biol Chem : — Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nat Med 24 : — Roles for Nkx3. Genes Dev 13 : — Radical prostatectomy or watchful waiting in early prostate cancer.
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol : — Genesis 47 : — Biswas SK , Mantovani A.
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11 : — Cancer Cell 31 : — Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling.
Cancer Cell 32 : — e Targeting bone metastases in prostate cancer: improving clinical outcome. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 31 : — Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 47 : — EMT in cancer. Nat Rev Cancer 18 : — Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet 13 : 7 — Cancer Epidemiol Biomarkers Prev 21 : — J Immunol : — Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.
Nat Commun 7 : Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol 20 : — Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20 : — Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.
Cell Rep 9 : — The molecular taxonomy of primary prostate cancer. Colony-stimulating factor 1 receptor CSF1R inhibitors in cancer therapy. J Immunother Cancer 5 : Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 6 : ra Nat Genet 41 : — Cancer Cell 19 : — Science : — A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Chaudhary B , Elkord E.
Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines Basel 4 : E Cancer genomics in clinical context. Trends Cancer 1 : 36 — RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov 4 : — Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation.
Cancer Cell 21 : — Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol 16 : — Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol 19 : — Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.
Oncotarget 8 : — Clevers H. Modeling development and disease with organoids. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 66 : 97 — Cooney KA. Inherited predisposition to prostate cancer: from gene discovery to clinical impact.
Trans Am Clin Climatol Assoc : 14 — Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Co-inoculation of prostate cancer cells with U enhances tumor growth and angiogenesis in vivo.
J Cell Biochem : 1 — 8. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22 : — The endocrinology and developmental biology of the prostate. Endocr Rev 8 : — Normal and abnormal development of the male urogenital tract.
Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 13 : — Medline Web of Science Google Scholar. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Lancet Oncol 12 : — Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer : — Nat Med 23 : — Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13 : — TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Eur Urol 60 : — N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30 : — Mechanism of lymph node metastasis in prostate cancer. Future Oncol 6 : — Mod Pathol 26 : — Dawson MA , Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell : 12 — Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res 14 : — Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet : — Abiraterone and increased survival in metastatic prostate cancer. Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns. Eur Urol 72 : — The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients.
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22 : — Dow LE. Trends Mol Med 21 : — Cancer Cell 7 : — J Clin Invest 87 : — Disease modeling in stem cell-derived 3D organoid systems.
Trends Mol Med 23 : — Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40 : — Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45 : — The genetic epidemiology of prostate cancer and its clinical implications.
Nat Rev Urol 11 : 18 — Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67 : 53 — Tumors as organs: complex tissues that interface with the entire organism.
Dev Cell 18 : — Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 : — Am J Surg Pathol 29 : — Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
Am J Surg Pathol 38 : — Am J Surg Pathol 40 : — Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 8 : e CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.
Cancer Res 75 : — Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Cancer Cell 18 : — Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. Epigenetic plasticity and the hallmarks of cancer. Science : eaal Cancer Immunol Res 5 : — Cancer Cell 27 : — Genomic hallmarks of localized, non-indolent prostate cancer.
Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology 80 : — Gabrilovich DI , Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system.
Nat Rev Immunol 9 : — Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12 : — Innate and adaptive immune cells in the tumor microenvironment.
Nat Immunol 14 : — ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun 5 : Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods : 9 — Organoid cultures derived from patients with advanced prostate cancer.
PLoS One 11 : e VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 34 : — Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial—mesenchymal transition and cancer stemness. Cancer Res 70 : — Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol : 58 — Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.
J Natl Cancer Inst 86 : — Circulating tumor cell counts are prognostic of overall survival in SWOG S a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32 : — Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics.
Identification of a cell of origin for human prostate cancer. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res 3 : — A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 3 : — DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis. Cancer Cell 28 : 97 — Prospects for combining targeted and conventional cancer therapy with immunotherapy.
Nat Rev Cancer 17 : — Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev 33 : — Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7 : — The mutational landscape of lethal castration-resistant prostate cancer. TRIM24 is an oncogenic transcriptional activator in prostate cancer.
Cancer Cell 29 : — Gubin MM. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12 : s — s. The evolutionary history of lethal metastatic prostate cancer.
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. Prostate 69 : — Tracking the clonal origin of lethal prostate cancer. J Clin Invest : — Prostate cancer cells promote osteoblastic bone metastases through Wnts.
Cancer Res 65 : — A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9 : Hanahan D , Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment.
Hanahan D , Weinberg RA. Hallmarks of cancer: the next generation. A novel human prostate-specific, androgen-regulated homeobox gene NKX3. Genomics 43 : 69 — HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
Lancet Oncol 17 : — Hensley PJ , Kyprianou N. Modeling prostate cancer in mice: limitations and opportunities. J Androl 33 : — Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 10 : — Hieronymus H , Sawyers CL. Traversing the genomic landscape of prostate cancer from diagnosis to death. Copy number alteration burden predicts prostate cancer relapse.
The androgen receptor recruits nuclear receptor corepressor N-CoR in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6 : Tumour exosome integrins determine organotropic metastasis. TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients.
TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2 : — Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 5 : Nat Genet 46 : — Cancer Discov 7 : — Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res 76 : — Huggins C , Hodges CV. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate.
Cancer Res 1 : — Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 63 : — Screening for prostate cancer. Cochrane Database Syst Rev doi: Cancer Res 64 : — A molecular signature predictive of indolent prostate cancer.
Sci Transl Med 5 : ra Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl : 65 — Abiraterone for prostate cancer not previously treated with hormone therapy.
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57 : — Jenuwein T , Allis CD. Translating the histone code. Epigenetics in prostate cancer: biologic and clinical relevance. Clin Cancer Res 23 : — A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Regulatory T cells: mechanisms of differentiation and function.
Annu Rev Immunol 30 : — A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis.
Nat Commun 4 : Annexin 2—CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow.
Mol Cancer Res 13 : — Influence of tumour micro-environment heterogeneity on therapeutic response. Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 4 : —
0コメント